Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$11.9 million.

  • Altimmune's Cash from Operations rose 5612.88% to -$11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.4 million, marking a year-over-year increase of 1505.97%. This contributed to the annual value of -$79.8 million for FY2024, which is 532.65% down from last year.
  • Latest data reveals that Altimmune reported Cash from Operations of -$11.9 million as of Q3 2025, which was up 5612.88% from -$19.3 million recorded in Q2 2025.
  • Altimmune's 5-year Cash from Operations high stood at -$11.9 million for Q3 2025, and its period low was -$27.1 million during Q3 2024.
  • Over the past 5 years, Altimmune's median Cash from Operations value was -$18.1 million (recorded in 2024), while the average stood at -$18.1 million.
  • In the last 5 years, Altimmune's Cash from Operations crashed by 35013.1% in 2021 and then surged by 5612.88% in 2025.
  • Over the past 5 years, Altimmune's Cash from Operations (Quarter) stood at -$22.0 million in 2021, then increased by 21.22% to -$17.3 million in 2022, then increased by 4.47% to -$16.5 million in 2023, then fell by 10.48% to -$18.3 million in 2024, then skyrocketed by 34.86% to -$11.9 million in 2025.
  • Its last three reported values are -$11.9 million in Q3 2025, -$19.3 million for Q2 2025, and -$16.8 million during Q1 2025.